These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 35678996)

  • 1. Comparative Efficacy of Brolucizumab in the Treatment of Neovascular Age-Related Macular Degeneration: A Systematic Literature Review and Network Meta-Analysis.
    Finger RP; Dennis N; Freitas R; Quenéchdu A; Clemens A; Karcher H; Souied EH
    Adv Ther; 2022 Aug; 39(8):3425-3448. PubMed ID: 35678996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Brolucizumab, Aflibercept, and Ranibizumab for the Treatment of Patients with Visual Impairment Due to Diabetic Macular Oedema: A Systematic Review and Network Meta-Analysis.
    Sydnor S; Chatterjee S; Cooney P; Kaur S; Macmillan T; Stewart D; Munro I; Bandeiras C; Paine A; Felizzi F
    Diabetes Ther; 2023 Jul; 14(7):1193-1216. PubMed ID: 37198521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
    Dugel PU; Koh A; Ogura Y; Jaffe GJ; Schmidt-Erfurth U; Brown DM; Gomes AV; Warburton J; Weichselberger A; Holz FG;
    Ophthalmology; 2020 Jan; 127(1):72-84. PubMed ID: 30986442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis.
    Yu JS; Carlton R; Agashivala N; Hassan T; Wykoff CC
    J Manag Care Spec Pharm; 2021 Jun; 27(6):743-752. PubMed ID: 34057392
    [No Abstract]   [Full Text] [Related]  

  • 5. Anti-vascular endothelial growth factor therapy for age-related macular degeneration: a systematic review and network meta-analysis.
    Tricco AC; Thomas SM; Lillie E; Veroniki AA; Hamid JS; Pham B; Lee T; Agarwal A; Sharpe JP; Scott A; Warren R; Brahmbhatt R; Macdonald E; Janoudi G; Muni RH; Francisconi CLM; Richter T; Straus SE
    Syst Rev; 2021 Dec; 10(1):315. PubMed ID: 34930439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Efficacy, Durability and Safety of Faricimab in the Treatment of Diabetic Macular Edema: A Systematic Literature Review and Network Meta-Analysis.
    Watkins C; Paulo T; Bührer C; Holekamp NM; Bagijn M
    Adv Ther; 2023 Dec; 40(12):5204-5221. PubMed ID: 37751021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of brolucizumab in age-related macular degeneration: A systematic review of real-world studies.
    Baumal CR; Sørensen TL; Karcher H; Freitas RL; Becher A; Balez S; Clemens A; Singer M; Kodjikian L
    Acta Ophthalmol; 2023 Mar; 101(2):123-139. PubMed ID: 36117281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy Outcomes of Brolucizumab Versus Aflibercept in Neovascular Age-Related Macular Degeneration Patients with Early Residual Fluid.
    Singh RP; Jhaveri C; Wykoff CC; Gale RP; Staurenghi G; Iida T; Koh A; B G; Gedif K; Singer M
    Ophthalmol Retina; 2022 May; 6(5):377-386. PubMed ID: 34968756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK.
    Ogura Y; Jaffe GJ; Cheung CMG; Kokame GT; Iida T; Takahashi K; Lee WK; Chang AA; Monés J; D'Souza D; Weissgerber G; Gedif K; Koh A
    Br J Ophthalmol; 2022 Jul; 106(7):994-999. PubMed ID: 34301613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2.
    Khanani AM; Kotecha A; Chang A; Chen SJ; Chen Y; Guymer R; Heier JS; Holz FG; Iida T; Ives JA; Lim JI; Lin H; Michels S; Quezada Ruiz C; Schmidt-Erfurth U; Silverman D; Singh R; Swaminathan B; Willis JR; Tadayoni R;
    Ophthalmology; 2024 Aug; 131(8):914-926. PubMed ID: 38382813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Anti-VEGF Therapy on the Disease Progression of Neovascular Age-Related Macular Degeneration: A Systematic Review and Model-Based Meta-Analysis.
    Luu KT; Seal J; Green M; Winskill C; Attar M
    J Clin Pharmacol; 2022 May; 62(5):594-608. PubMed ID: 34783362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.
    Carrasco J; Pietsch GA; Nicolas MP; Koerber C; Bennison C; Yoon J
    Adv Ther; 2020 Jan; 37(1):300-315. PubMed ID: 31728825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of faricimab for neovascular age-related macular degeneration: a systematic review and network meta-analysis.
    Samacá-Samacá D; Hernández-Castillo C; Prieto-Pinto L; Rodríguez F; Sardi C; Ocampo H; Kock J; Hernández F
    BMJ Open Ophthalmol; 2024 Jul; 9(1):. PubMed ID: 39043575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
    Dugel PU; Singh RP; Koh A; Ogura Y; Weissgerber G; Gedif K; Jaffe GJ; Tadayoni R; Schmidt-Erfurth U; Holz FG
    Ophthalmology; 2021 Jan; 128(1):89-99. PubMed ID: 32574761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluid Control in Neovascular Age-Related Macular Degeneration with Brolucizumab: An Analysis of the HAWK and HARRIER Phase 3 Trials.
    Regillo C; Singh R; Hamilton R; Gedif K; Best C; Koh A; Holz FG
    Ophthalmologica; 2022; 245(5):403-412. PubMed ID: 35468601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials.
    Nguyen CL; Oh LJ; Wong E; Wei J; Chilov M
    BMC Ophthalmol; 2018 May; 18(1):130. PubMed ID: 29843663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Anti-Vascular Endothelial Growth Factor Monotherapies for Neovascular Age-Related Macular Degeneration: A Mixed Treatment Comparison.
    Zhang Y; Gao S; Li X; Huang X; Zhang Y; Chang T; Cai Z; Zhang M
    Front Pharmacol; 2021; 12():797108. PubMed ID: 34992542
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial.
    Mori R; Honda S; Gomi F; Tsujikawa A; Koizumi H; Ochi H; Ohsawa S; Okada AA;
    Jpn J Ophthalmol; 2023 May; 67(3):301-310. PubMed ID: 37039948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema.
    Brown DM; Emanuelli A; Bandello F; Barranco JJE; Figueira J; Souied E; Wolf S; Gupta V; Ngah NF; Liew G; Tuli R; Tadayoni R; Dhoot D; Wang L; Bouillaud E; Wang Y; Kovacic L; Guerard N; Garweg JG
    Am J Ophthalmol; 2022 Jun; 238():157-172. PubMed ID: 35038415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brolucizumab for recalcitrant macular neovascularization in age-related macular degeneration with pigment epithelial detachment.
    Chronopoulos A; Huynh E; Ashurov A; Schutz JS; Jonas JB; Hattenbach LO
    Eur J Ophthalmol; 2024 Mar; 34(2):487-496. PubMed ID: 37461836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.